drugset / Trial / NCT05109728
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Timeline
- Start
- 2022-05-10
- Primary completion
- 2025-12-03
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-DOTATATE | Peptide | 100 unknown | — |
| Subject | 177Lu-DOTATATE | Peptide | 150 unknown | — |
| Subject | 177Lu-DOTATATE | Peptide | 200 unknown | — |
| Subject | 177Lu-DOTATATE | Peptide | 250 unknown | — |